Nov 23, 2022 / 03:00PM GMT
Operator
Greetings, and welcome to the Nykode Therapeutics' third-quarter 2022 financial results call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the call over to Chief Executive Officer, Michael Engsig. Thank you. You may begin.
Michael Engsig - Nykode Therapeutics ASA - CEO
Thank you very much. And also from our side, a warm welcome to all participants joining here, both from Europe and the early birds from the US. I'll start out with a quick note on the forward-looking statements. We assume you're all familiar with that. So on that note, we'll move forward. With me today here at this third-quarter call, I'm very pleased to have Agnete Fredriksen, our Co-Founder and Chief Business Officer; as well as Harald Gurvin, our Chief Financial Officer. I'm Michael Engsig, CEO of Nykode.
A quick introduction to those of you who are new to Nykode: Nykode is a Norwegian-based immunotherapy company. We're entirely focused to building the leading immunotherapy company. And we're focused, too, on our dual strategy,
Q3 2022 Nykode Therapeutics ASA Earnings Call Transcript
Nov 23, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers